Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diprospan is an injectable corticosteroid combination consisting of betamethasone dipropionate and betamethasone sodium phosphate. It is designed to provide both rapid and prolonged anti-inflammatory, anti-rheumatic, and anti-allergic effects. The betamethasone sodium phosphate component is highly soluble and provides immediate activity, while the betamethasone dipropionate component is sparingly soluble and serves as a repository for sustained release over several weeks. In clinical research conducted by the First Affiliated Hospital of Fujian Medical University, Diprospan is being investigated as an additive to local infiltration analgesia (LIA) to optimize postoperative pain management and enhance recovery in patients undergoing total knee arthroplasty (TKA).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diprospan.